Jazz Pharmaceuticals Seeks Injunction Against Avadel’s FDA Filing Amid Legal Battle Over Sleep Disorder Drug Lumryz

In a recent legal maneuver, Jazz Pharmaceuticals has requested that a Delaware federal judge prevent Avadel CNS Pharmaceuticals from pursuing U.S. Food and Drug Administration approval for its drug Lumryz, intended to treat idiopathic hypersomnia. This action follows a decision by the Federal Circuit to remand the case to a lower court. Jazz’s motion adds another layer to the complex legal proceedings surrounding the competitive pharmaceutical market for sleep disorder treatments. The ongoing efforts to secure market dominance underscore the high stakes involved for both companies in the highly competitive field of sleep disorder pharmaceuticals. For more information on the case developments, visit Law360.